Bharat Parenterals Ltd — Important, 20-05-2026: Company Update

Bharat Parenterals reported flat consolidated revenue for FY26 at INR 345.4 Cr, but saw EBITDA jump 485% to INR 15.8 Cr, with PAT loss narrowing significantly. This was primarily driven by Innoxel Lifesciences, which grew revenue 174% to INR 72.4 Cr and became EBITDA positive in Q4. Innoxel secured critical US FDA and EUGMP clearances, enabling commercial supply to key markets. Varenyam Healthcare also turned profitable, growing revenue 13.7%. The standalone business faced export delays and facility upgrades, declining 23% to INR 234 Cr. For FY27, management projects strong growth, especially from Innoxel (35-45% revenue) and Varenyam (20-25%).